Search clinical trials for: Tildrakizumab

Total 25 results

University of California, San Francisco
Sun Pharmaceutical Industries Limited

Recruiting

Predicting Inflammatory Skin Disease Response to IL-23 Blockade

Psoriasis Vulgaris

United States
Almirall, S.A.

Active, not recruiting

Observational Study of Tildrakizumab in Patients With Moderate to Severe Plaque Psoriasis in Routine Clinical Practice (SAIL)

Plaque Psoriasis

Germany, Austria, Italy, Netherlands
Almirall, S.A.

Recruiting

A Study of Tildrakizumab in the Treatment of Genital Psoriasis (CZATCH-Genital-PsO)

Genital Psoriasis

Austria
Sun Pharmaceutical Industries Limited

Completed

A Real World Study Evaluating the Long-Term Quality of Life of Tildrakizumab in Adult Patients With Psoriasis

Psoriasis

United States
Marcelo F. Di Carli, MD, FACC

Recruiting

MIcrovascular dysfuNction In Moderate-severe Psoriasis (MINIMA)

Psoriasis

United States
Sun Pharmaceutical Industries Limited

Active, not recruiting

Efficacy and Safety Study of Tildrakizumab in the Treatment of Nail Psoriasis

Chronic Plaque Psoriasis | Moderate to Severe Nail Psoriasis

United States, Australia
Almirall, S.A.

Recruiting

A Study to Assess the Effects of Switching From a Biologic Treatment to Tildrakizumab Using Patient-reported Outcomes in Adult Participants With Moderate to Severe Plaque Psoriasis

Plaque Psoriasis

Austria
Merck Sharp & Dohme LLC

Completed

A Study to Determine the Optimal Dose of Tildrakizumab (SCH 900222/MK-3222) for the Treatment of Moderate-to-severe Chronic Plaque Psoriasis (P05495) (MK-3222-003)

Psoriasis
Almirall, S.A.

Terminated

Long-Term Treatment Effect With Tildrakizumab in Participants With Plaque Psoriasis (MODIFY)

Plaque Psoriasis

Poland
Medical College of Wisconsin

Active, not recruiting

Tildrakizumab for Prevention of Acute Graft-Versus-Host Disease

Hematologic Malignancies

United States
Sun Pharmaceutical Industries Limited

Recruiting

Safety Study for Prospective Assessment of Pregnancy Outcomes in Patients Treated With Tildrakizumab

Pregnancy Related

United States
Sun Pharmaceutical Industries Limited

Completed

A Study to Evaluate the Efficacy and Safety of Subcutaneous MK-3222, Followed by an Optional Long-Term Safety Extension Study, in Participants With Moderate-to-Severe Chronic Plaque Psoriasis (MK-3222-010) (reSURFACE 1)

Plaque Psoriasis
Premier Specialists, Australia

Active, not recruiting

Pilot Study Assessing the Effect of Tildrakizumab in Vitiligo (TILDVIT-1227)

Skin Diseases | Vitiligo | Hypopigmentation | Skin and Connective Tissue Diseases | Pigmentation Disorder | Biologic

Australia
Carlos Wambier
Brown University; Sun Pharmaceutical Industries Limited; Lifespan; Ocean State...

Active, not recruiting

Effects of Tildrakizumab on Epigenetic Age

Psoriasis | Aging | Inflammation; Skin | Epigenetic Disorder

United States
Almirall, S.A.

Completed

Efficacy and Safety of Tildrakizumab 100 Milligrams (mg) in Participants With Moderate-Severe Chronic Plaque Psoriasis and Its Impact on Their Quality of Life (TRIBUTE) (TRIBUTE)

Plaque Psoriasis

Spain, Italy
University of California, San Francisco
Sun Pharmaceutical Industries Limited

Recruiting

Psoriatic Immune Response to Tildrakizumab

Psoriasis Vulgaris

United States
Shenzhen Kangzhe Pharmaceutical Co., Ltd.

Completed

A Phase Ⅲ Study to Evaluate Tildrakizumab in the Treatment of Chinese Subjects With Moderate to Severe Plaquetype Psoriasis

Plaque Psoriasis

China
Sun Pharmaceutical Industries Limited

Completed

A Study to Evaluate the Efficacy and Safety/Tolerability of Subcutaneous Tildrakizumab (SCH 900222/MK-3222) in Participants With Moderate-to-Severe Chronic Plaque Psoriasis Followed by a Long-term Extension Study (MK-3222-011) (reSURFACE 2)

Plaque Psoriasis
Brigham and Women's Hospital
Joseph Merola

Not yet recruiting

The Effects of Tildrakizumab in Treatment of Bullous Pemphigoid

Pemphigoid, Bullous
Radboud University Medical Center
University Hospital, Ghent; ZonMw: The Netherlands Organisation for Health... and other collaborators

Active, not recruiting

Dose Reduction of IL17 and IL23 Inhibitors in Psoriasis (BeNeBio)

Psoriasis | Psoriasis Vulgaris

Netherlands, Belgium
Novartis Pharmaceuticals

Completed

A Phase 3 Study of Efficacy and Safety of Remibrutinib in the Treatment of CSU in Adults Inadequately Controlled by H1 Antihistamines (REMIX-1)

Chronic Spontaneous Urticaria

Hungary, Taiwan, Italy, Korea, Republic of, Australia, France, Bulgaria, Czechia, Turkey, India, United States, Argentina, Mexico, Spain, Japan, Colombia, Russian Federation, Singapore, Puerto Rico
Almirall, S.A.

Active, not recruiting

Observational Real-world Evidence (RWE) Study to Assess Patient-reported Wellbeing Using Tildrakizumab in Live Setting - POSITIVE Study (POSITIVE)

Plaque Psoriasis

Germany
Almirall, S.A.

Completed

Efficacy and Safety of Tildrakizumab in Participants With Moderate-to-Severe Chronic Plaque Psoriasis Who Are Non-Responders to Dimethyl Fumarate Therapy (TRANSITION)

Plaque Psoriasis

United Kingdom, Germany
Institute of Cancer Research, United Kingdom
Sun Pharmaceutical Industries Limited

Active, not recruiting

Abiraterone Acetate in Combination With Tildrakizumab (ACTIon)

Metastatic Castration Resistant Prostate Cancer

United Kingdom, Switzerland
Sun Pharmaceutical Industries Limited

Recruiting

A Study of Tildrakizumab in Pediatric Subjects With Chronic Plaque Psoriasis

Moderate-to-severe Chronic Plaque Psoriasis

United States, Hungary, India, Poland, Slovakia, Spain

Search clinical trials for: Tildrakizumab

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Albania

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations